Clinical Trials

Inclusion Criteria:

• Written informed consent prior to completing any study-specific procedure
• Histologically- or cytologically-confirmed advanced/metastatic solid tumor or lymphoma that is refractory to standard therapies, or the patient refuses standard therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
• Adequate hematological and biological function
• Female patients of childbearing potential must have a negative serum pregnancy test
• Male and female patients must agree to use a highly reliable method of birth control.

Exclusion Criteria:

• Active central nervous system tumors or metastases
• Treatment with prohibited medications (eg, concurrent anti-cancer therapy including other chemotherapy, radiation (local radiation for palliative care is permitted), hormonal anti-cancer treatment, biologic therapy, or immunotherapy) < 28 days prior to the first day of study treatment
• Active or prior autoimmune disorder within the past 2 years
• History of primary immunodeficiency, solid organ transplantation, or tuberculosis
• Any plan to receive a live attenuated vaccine during study treatment
• History of human immunodeficiency virus infection (testing is not required)
• Active/chronic hepatitis B or C
• Females who are pregnant or breastfeeding